High titer antibodies against melanoma differentiation antigens (TRP1/TYRP1, TRP2/TYRP2, gp100, MelanA/MART1) were observed in responder group of melanoma patients treated with ICI mAbs (monotherapies with Nivolumab, Pembrolizumab or Ipilimumab, or the combination of Nivolumab and Ipilimumab)28,29. The gene discussed is TYRP1; the disease is melanoma.